After hours trading shows AYA.AX stock at A$3.06, down -10.00% on the session as investors reassess AI commercialization timing. The drop follows thinner volume of 373,561.00 shares and comes after a run above the 50-day average of A$3.91. This piece reviews Artrya Limited (AYA.AX) on the ASX, links financial ratios to price action, and flags the AI adoption milestones investors will watch in the coming months.

Price action and immediate drivers

Artrya (AYA.AX) closed after hours at A$3.06 on 03 Mar 2026, down -10.00% from the previous close of A$3.40. Trading volume hit 373,561.00 shares, below the average of 623,211.00, suggesting selective selling rather than broad panic. The share move ties to AI deployment timelines and investor scrutiny of revenue conversion from Artrya’s Salix software.

Business model: AI product and commercial traction

Artrya Limited uses AI to detect coronary artery disease with its Salix software. The company sells cloud-based services to imaging centres and hospitals, where sales cycles can be long and contractual. Market reaction today reflects uncertainty over the pace of clinical adoption and recurring revenue growth in 2026.

Financials and valuation metrics

Key figures show market cap A$351,642,000.00 and shares outstanding 113,800,000.00. Earnings per share is -0.17 with a negative PE of -18.18, and cash per share stands at 0.61. The balance of strong cash buffers and negative margins points to ongoing investment in R&D and commercial expansion.

Technicals and trading setup for AI stocks

Technically AYA.AX shows RSI near 40.02, below neutral but not deeply oversold. The 50-day average sits at A$3.91 and the 200-day average at A$2.54, which gives mixed trend signals. Short-term traders will watch the A$2.96 Bollinger lower band and the MACD histogram for confirmation of momentum change.

Meyka grade, forecast and analyst context

Meyka AI rates AYA.AX with a score of 63.48 out of 100 — Grade B, suggestion HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects a yearly price of A$7.41, implying an upside of 142.0% from the current A$3.06. Forecasts are model-based projections and not guarantees.

Risks, catalysts and what to watch

Main risks are slow hospital procurement cycles, tighter than expected reimbursement, and execution on enterprise sales. Catalysts include new commercial contracts, regulatory updates, and quarterly revenue beats. Investors focusing on AI stocks should watch upcoming clinical partnerships and the earnings announcement scheduled for 2026-08-27.

Final Thoughts

AYA.AX stock traded lower after hours to A$3.06 on 03 Mar 2026 as investors weighed near-term revenue clarity against long-term AI opportunity. The company sits on cash buffers but reports negative EPS -0.17 and a negative PE -18.18, reflecting current unprofitable operations. Technicals give a mixed picture; the 50-day is A$3.91 and the 200-day is A$2.54. Meyka AI’s forecast model projects a yearly price of A$7.41, implying roughly 142.0% upside versus today. That projection assumes successful commercial rollouts and improved revenue conversion. These forecasts are model-based projections and not guarantees. Use this as a framework: monitor contract announcements, revenue beats, and quarterly cash burn. For real-time filings and company updates see the Reuters company page and Artrya’s site for primary documents source and internal coverage on our Meyka page Meyka AYA.AX stock. Meyka AI provides this as data-driven market analysis, not personal financial advice.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.